Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company`s onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Website: cardiffoncology.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. Gross margin is high, +100.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -3.3% (LTM)

Entry Point: Share price is 31.3% higher than minimum and 78.7% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: CRDF
Share price, USD:  (-11.3%)1.26
year average price 2.6159  


year start price 3.0200 2025-06-18

max close price 4.4500 2025-07-17

min close price 1.3000 2026-06-16

current price 1.2600 2026-06-17
Common stocks: 43 306 101

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 61
Net Debt ($m): -11
EV (Enterprise Value): 50
Price to Book: 1.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-28seekingalpha.com

Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript

2026-01-27globenewswire.com

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

2025-10-25seekingalpha.com

Cardiff Oncology: Preparing For A Defining 2026

2025-10-22seekingalpha.com

Cardiff Oncology's Promising Cancer Breakthrough Ahead - Why I Choose To Buy

2025-07-30benzinga.com

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

2025-07-30seekingalpha.com

Cardiff Oncology: Data Update Resolves Some Signals

2025-06-27seekingalpha.com

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

2025-06-17marketwatch.com

Cardiff Oncology Names Roger Sidhu as Medical Chief

2025-05-14zacks.com

Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know

2025-05-02seekingalpha.com

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-07-29 2024-11-07 2024-08-08 2024-05-02 2023-11-02 2023-08-09 2023-05-04 2022-11-03
acceptedDate 2025-11-06 16:00:49 2025-07-29 16:00:21 2025-02-27 16:00:24 2024-11-07 16:00:30 2024-08-08 16:00:13 2024-05-02 16:00:33 2024-02-29 16:00:21 2023-11-02 16:02:08 2023-08-09 16:01:02 2023-05-04 16:00:51 2023-03-02 16:01:11 2022-11-03 16:00:17 2022-02-24 16:00:07 2021-02-25 16:01:11
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 120 000 121 000 683 000 165 000 163 000 205 000 488 000 141 000 108 000 83 000 386 000 93 000 359 000 366 000
costOfRevenue 0 12M 0 0 105 000 102 000 0 107 000 98 000 0 0 0 0 0
grossProfit 120 000 -11M 683 000 165 000 58 000 103 000 488 000 34 000 10000 83 000 386 000 93 000 359 000 366 000
grossProfitRatio 1 -94.702 1 0.356 0.502 0.241 0.093 1 1
researchAndDevelopmentExpenses 8M 12M 37M 10M 9M 8M 33M 8M 8M 9M 27M 6M 17M 11M
generalAndAdministrativeExpenses 4M 0 12M 3M 3M 3M 13M 3M 4M 3M 13M 3M 12M 8M
sellingAndMarketingExpenses 0 0 0 400 000 459 000 -102 000 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 4M 0 12M 3M 3M 3M 13M 3M 4M 3M 13M 3M 12M 8M
otherExpenses 0 -8M 0 0 -38 000 -4000 0 21 000 5000 -111 000 0 0 0 0
operatingExpenses 12M 3M 49M 13M 13M 11M 46M 11M 12M 12M 40M 9M 29M 19M
costAndExpenses 12M 15M 49M 13M 13M 11M 46M 11M 12M 12M 40M 9M 29M 19M
interestIncome 716 000 835 000 3M 741 000 805 000 926 000 4M 1M 1M 940 000 2M 458 000 264 000 90 000
interestExpense 0 0 0 0 0 0 0 0 0 -829 000 0 458 000 0 2000
depreciationAndAmortization 494 000 94 000 404 000 101 000 105 000 102 000 398 000 107 000 98 000 90 000 236 000 81 000 451 000 466 000
ebitda -11M -15M -48M -13M -12M -11M -45M -11M -12M -12M -40M -9M -28M -19M
ebitdaratio -89.7 -121.347 -75.758 -76.319 -52.834 -75.979 -112.13 -144.12 -95.828
operatingIncome -12M -15M -49M -13M -13M -11M -45M -11M -12M -12M -40M -9M -29M -19M
operatingIncomeRatio -99.783 -122.124 -76.37 -76.963 -53.332 -76.738 -113.037 -145.205 -96.699
totalOtherIncomeExpensesNet 716 000 834 000 3M 740 000 767 000 922 000 4M 21 000 5000 829 000 1M 422 000 564 000 -221 000
incomeBeforeTax -11M -14M -45M -12M -12M -10M -41M -10M -11M -11M -39M -9M -28M -19M
incomeBeforeTaxRatio -93.817 -115.231 -71.885 -72.258 -48.834 -69.014 -103.241 -135.217 -92.161
incomeTaxExpense 0 0 0 0 0 58 724 0 -1M -1M -829 000 0 -422 000 0 0
netIncome -11M -14M -45M -12M -12M -10M -41M -10M -11M -10M -39M -8M -28M -19M
netIncomeRatio -93.817 -115.231 -71.848 -72.258 -48.834 -69.014 -103.241 -125.229 -87.624
eps -0.17 -0.21 -0.95 -0.25 -0.26 -0.22 -0.93 -0.22 -0.25 -0.23 -0.89 -0.19 -0.73 -1.08
epsdiluted -0.17 -0.21 -0.25 -0.26 -0.22 -0.22 -0.25 -0.23 -0.19
weightedAverageShsOut 67M 67M 48M 47M 45M 45M 45M 45M 45M 45M 44M 43M 39M 21M
weightedAverageShsOutDil 67M 67M 48M 47M 45M 45M 45M 45M 45M 45M 44M 43M 39M 21M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-29 2023-03-02 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 3M 4M 2M 264 000 88 000
ebit -49M -45M -40M -29M -19M
nonOperatingIncomeExcludingInterest 0 0 0 0 219 000
netIncomeFromContinuingOperations -45M -41M -39M -28M -19M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -45M -41M -39M -28M -23M
epsDiluted -0.95 -0.93 -0.89 -0.73 -1.08

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-07-29 2024-11-07 2024-08-08 2024-05-02 2023-11-02 2023-08-09 2023-05-04 2022-11-03
acceptedDate 2025-11-06 16:00:49 2025-07-29 16:00:21 2025-02-27 16:00:24 2024-11-07 16:00:30 2024-08-08 16:00:13 2024-05-02 16:00:33 2024-02-29 16:00:21 2023-11-02 16:02:08 2023-08-09 16:01:02 2023-05-04 16:00:51 2023-03-02 16:01:11 2022-11-03 16:00:17 2022-02-24 16:00:07 2021-02-25 16:01:11
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 10M 11M 51M 13M 26M 19M 22M 15M 19M 15M 16M 19M 12M 131M
shortTermInvestments 50M 60M 40M 45M 35M 49M 53M 66M 70M 82M 89M 96M 129M 0
cashAndShortTermInvestments 61M 71M 92M 58M 60M 67M 75M 81M 89M 97M 105M 114M 141M 131M
netReceivables 254 000 526 000 773 000 618 000 451 000 393 000 288 000 198 000 161 000 676 000 771 000 650 000 535 000 320 000
inventory 0 0 0 0 0 1 0 0 1 0 0 0 0 0
otherCurrentAssets 956 000 2M 3M 1M 1M 2M 2M 2M 3M 4M 5M 5M 0 0
totalCurrentAssets 62M 74M 95M 59M 62M 70M 77M 84M 93M 102M 111M 120M 146M 133M
propertyPlantEquipmentNet 1M 2M 2M 2M 3M 3M 3M 3M 3M 3M 4M 4M 3M 967 000
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 549 000 401 000 69 000 1M 1M 1M 1M 1M 1M 1M 1M 184 000 239 000 404 000
totalNonCurrentAssets 2M 2M 2M 4M 4M 4M 4M 5M 5M 5M 5M 4M 3M 1M
otherAssets 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 64M 76M 97M 63M 66M 74M 82M 88M 97M 107M 116M 124M 150M 135M
accountPayables 2M 6M 5M 5M 5M 5M 2M 2M 3M 3M 2M 1M 1M 1M
shortTermDebt 726 000 721 000 0 707 000 1M 696 000 0 688 000 683 000 679 000 0 674 000 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 12M 10M 3M 7M 6M 6M 5M 6M 6M 5M 2M 6M 1M 2M
totalCurrentLiabilities 15M 17M 13M 13M 13M 12M 10M 9M 9M 8M 8M 8M 7M 6M
longTermDebt 284 000 464 000 0 979 000 1M 1M 0 2M 2M 2M 0 2M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 0 0 0 0 0 0 75 000 0 441 000
totalNonCurrentLiabilities 284 000 464 000 813 000 979 000 1M 1M 1M 2M 2M 2M 2M 2M 3M 450 000
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 1M 1M 2M 2M 2M 1M 2M 2M 2M 3M 3M 3M 3M 869 000
totalLiabilities 15M 17M 14M 14M 14M 13M 12M 11M 11M 10M 10M 10M 9M 7M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 1000 1000
commonStock 7000 7000 7000 5000 5000 4000 4000 4000 4000 4000 4000 4000 4000 4000
retainedEarnings -423M -412M -384M -372M -361M -349M -340M -330M -320M -309M -298M -290M -260M -231M
accumulatedOtherComprehensiveIncomeLoss 50 000 17 000 34 000 82 000 -97 000 -132 000 -67 000 -407 000 -431 000 -76 000 -395 000 -779 000 -142 000 0
othertotalStockholdersEquity 472M 470M 422M 413M 410M 408M 407M 406M 404M
totalStockholdersEquity 49M 59M 83M 49M 52M 61M 70M 78M 87M 97M 106M 113M 140M 128M
totalEquity 49M 59M 83M 49M 52M 61M 70M 78M 87M 97M 106M 113M 140M 128M
totalLiabilitiesAndStockholdersEquity 64M 76M 63M 66M 74M 88M 97M 107M 124M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 64M 76M 97M 63M 66M 74M 82M 88M 97M 107M 116M 124M 150M 135M
totalInvestments 50M 60M 40M 45M 35M 49M 53M 66M 70M 82M 89M 96M 129M 0
totalDebt 1M 1M 2M 2M 2M 2M 2M 2M 2M 3M 3M 3M 3M 869 000
netDebt -9M -10M -50M -11M -24M -17M -20M -13M -17M -12M -14M -16M -9M -130M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-29 2023-03-02 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 773 000 288 000 771 000 535 000 320 000
otherReceivables 0 0 0 0 0
prepaids 0 0 0 5M 2M
totalPayables 5M 2M 2M 2M 2M
otherPayables 0 0 0 414 000 390 000
accruedExpenses 5M 3M 3M 3M 2M
capitalLeaseObligationsCurrent 710 000 691 000 675 000 551 000 860 000
capitalLeaseObligationsNonCurrent 813 000 1M 2M 3M 9000
treasuryStock 0 0 0 0 0
additionalPaidInCapital 467M 409M 405M 401M 362M
otherTotalStockholdersEquity 0 0 0 -139 000 -2M

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF CRDF
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-07-29 2024-11-07 2024-08-08 2024-05-02 2023-11-02 2023-08-09 2023-05-04 2022-11-03
acceptedDate 2025-11-06 16:00:49 2025-07-29 16:00:21 2025-02-27 16:00:24 2024-11-07 16:00:30 2024-08-08 16:00:13 2024-05-02 16:00:33 2024-02-29 16:00:21 2023-11-02 16:02:08 2023-08-09 16:01:02 2023-05-04 16:00:51 2023-03-02 16:01:11 2022-11-03 16:00:17 2022-02-24 16:00:07 2021-02-25 16:01:11
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -11M -14M -45M -12M -12M -10M -41M -10M -11M -11M -39M -9M -28M -19M
depreciationAndAmortization 494 000 229 000 404 000 101 000 105 000 102 000 398 000 107 000 98 000 90 000 236 000 81 000 451 000 466 000
deferredIncomeTax 0 0 0 0 0 0 0 -10M -11M 0 0 0 1M 0
stockBasedCompensation 1M 2M 5M 1M 1M 1M 5M 955 000 2M 1M 4M 1M 3M 2M
changeInWorkingCapital -1M 4M 3M -3M 1M 1M 7M 1M 3M 2M -380 000 -148 000 -2M -654 000
accountsReceivables 272 000 -121 000 -484 000 -167 000 -58 000 -105 000 483 000 -37 000 515 000 95 000 -236 000 0 -215 000 -117 000
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 0 4M 3M -1000 673 000 1M 3M 135 000 1M 203 000 1M 0 719 000 0
otherWorkingCapital -1M -143 000 671 000 -2M 776 000 -109 000 3M 925 000 976 000 1M -1M 0 -2M -537 000
otherNonCashItems -252 000 -301 000 -598 000 3M 647 000 -138 000 -921 000 10M 11M -163 000 772 000 115 000 2M 1M
netCashProvidedByOperatingActivities -11M -8M -38M -10M -9M -8M -31M -8M -7M -9M -34M -7M -23M -16M
investmentsInPropertyPlantAndEquipment -18 000 -26 000 -80 000 0 0 -80 000 -582 000 -315 000 -251 000 -8000 -892 000 -448 000 -205 000 -211 000
acquisitionsNet 0 0 0 0 0 0 0 315 000 251 000 0 -114 000 0 205 000 0
purchasesOfInvestments -9M -20M -24M -23M 0 -919 000 -70M -17M -14M -37M -91M -23M -174M 0
salesMaturitiesOfInvestments 20M 15M 37M 13M 14M 6M 107M 21M 25M 45M 130M 29M 43M 0
otherInvestingActivites 0 0 0 14M 5M -315 000 -251 000 0 43 000
netCashUsedForInvestingActivites 10M -5M -9M 14M 5M 4M 11M 7M 5M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 0 0 7M 2M 107 000 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 -6000 -6000 0 0 -6000 0 0
otherFinancingActivites 25 000 0 7M 2M 107 000 6000 6000 0 75 000
netCashUsedProvidedByFinancingActivities 25 000 0 7M 2M 107 000 -6000 -6000 0 75 000
effectOfForexChangesOnCash 0 -1 0 0 0 0 0 -6M -16M 0 0 0 0 0
netChangeInCash -649 000 -13M 30M -12M 7M -3M 5M -4M 4M -1M 4M -2M -119M 121M
cashAtEndOfPeriod 10M 11M 51M 13M 26M 19M 22M 15M 19M 15M 16M 19M 12M 131M
cashAtBeginningOfPeriod 11M 24M 22M 26M 19M 22M 16M 19M 15M 16M 12M 21M 131M 10M
operatingCashFlow -11M -8M -38M -10M -9M -8M -31M -8M -7M -9M -34M -7M -23M -16M
capitalExpenditure -18 000 -26 000 -80 000 0 0 -80 000 -582 000 -315 000 -251 000 -8000 -892 000 -448 000 -205 000 -211 000
freeCashFlow -11M -8M -38M -10M -9M -8M -31M -8M -7M -9M -35M -8M -23M -17M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-29 2023-03-02 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 114 000 -205 000 0
netCashProvidedByInvestingActivities 14M 36M 38M -131M -211 000
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 53M 0 75 000 34M 112M
netCommonStockIssuance 53M 0 75 000 34M 112M
commonStockIssuance 53M 0 75 000 34M 112M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 -414 000 -24 000 0
commonDividendsPaid 0 0 -414 000 -24 000 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 373 000 0 414 000 1M 25M
netCashProvidedByFinancingActivities 54M 0 75 000 35M 137M
incomeTaxesPaid 0 1000 2000 1000 1000
interestPaid 0 0 0 0 0

Earning call transcript

2024 q4
2025-02-27 ET (fiscal 2024 q4)
2024 q2
2024-08-10 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-29 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q1
2024-05-03 ET (fiscal 2023 q1)

Press-releases

Show financial reports only

2026-05-14 20:10 ET
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
2026-04-28 20:01 ET
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-04-27 11:00 ET
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
2026-04-21 14:00 ET
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
2026-04-17 ET
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
2026-04-09 ET
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
2026-03-19 ET
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
2026-02-26 ET
Cardiff Oncology to Participate in Three Upcoming Investor Conferences 
2026-02-24 ET
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
2026-02-19 ET
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2026-01-27 ET
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
2026-01-27 ET
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
2025-12-08 ET
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025
2025-12-08 ET
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference
2025-11-24 ET
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference
2025-11-06 ET
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update
2025-11-04 ET
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
2025-10-02 ET
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
2025-08-28 ET
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
2025-07-29 ET
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
2025-07-29 ET
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
2025-06-17 ET
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
2025-06-02 ET
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
2025-05-08 ET
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
2025-04-23 ET
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
2025-04-15 ET
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-04-15 ET
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
2025-03-08 ET
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
2025-02-27 ET
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
2025-02-24 ET
Cardiff Oncology to Present at Upcoming Investor Conferences
2025-02-20 ET
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
2024-12-10 ET
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
2024-12-10 ET
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
2024-11-19 ET
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
2024-11-07 ET
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
2024-10-30 20:30 ET
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
2024-08-08 20:05 ET
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
2024-08-01 20:05 ET
Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update
2024-05-29 20:05 ET
Cardiff Oncology to Present at the Jefferies Healthcare Conference
2024-05-13 20:05 ET
Cardiff Oncology to Present at Upcoming Investor Conferences in May
2024-05-02 20:05 ET
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
2024-04-25 20:05 ET
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
2024-04-08 20:05 ET
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
2024-03-06 21:05 ET
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
2024-02-29 21:07 ET
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
2024-02-29 21:06 ET
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
2024-02-29 21:05 ET
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
2024-02-26 13:00 ET
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
2024-02-22 13:00 ET
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
2024-01-17 15:30 ET
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
2023-11-20 21:05 ET
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference
2023-11-02 20:05 ET
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
2023-10-26 20:05 ET
Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update
2023-09-26 20:05 ET
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
2023-09-05 12:00 ET
Cardiff Oncology to Present at Upcoming Investor Conferences in September
2023-08-09 20:05 ET
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
2023-08-07 20:05 ET
Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship
2023-07-24 21:09 ET
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-06-20 21:22 ET
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-06-05 12:00 ET
Cardiff Oncology to Present at the Jefferies Healthcare Conference
2023-05-04 20:10 ET
Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update
2023-03-28 12:00 ET
Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer
2023-03-06 13:15 ET
Cardiff Oncology Formally Introduces Scientific Advisory Board
2023-03-02 21:10 ET
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
2023-02-27 13:15 ET
Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference
2023-02-02 13:00 ET
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer
2023-01-10 13:00 ET
Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference
2022-11-21 15:52 ET
Cardiff Oncology to Present at Upcoming Investor Conferences
2022-11-08 13:15 ET
Cardiff Oncology to Present at the Jefferies London Healthcare Conference
2022-11-03 20:10 ET
Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates
2022-09-12 20:05 ET
Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates
2022-09-10 11:30 ET
Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022
2022-09-08 12:15 ET
Cardiff Oncology to Present at Upcoming Investor Conferences in September
2022-09-06 12:00 ET
Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022
2022-08-29 12:00 ET
Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022
2022-08-04 20:10 ET
Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates
2022-07-05 12:30 ET
Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022
2022-05-17 12:30 ET
Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference
2022-05-05 20:10 ET
Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates
2022-04-12 20:00 ET
Cardiff Oncology Announces Departure of Chief Medical Officer
2022-04-08 17:05 ET
Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting
2022-04-08 17:05 ET
Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models
2022-03-22 13:05 ET
Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC
2022-03-08 21:45 ET
Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting
2022-03-01 13:30 ET
Cardiff Oncology to Participate in Cowen's 42nd Annual Healthcare Conference
2022-02-24 21:10 ET
Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights
2022-01-31 23:22 ET
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-01-20 18:46 ET
Cardiff Oncology to Present at the B. Riley Securities 2022 Oncology Conference
2022-01-18 22:00 ET
Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival
2022-01-11 13:00 ET
Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs
2022-01-10 13:00 ET
Cardiff Oncology to Host Conference Call and Webcast to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Being Presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
2022-01-04 13:00 ET
Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual Conference
2021-12-10 13:30 ET
Cardiff Oncology Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
2021-12-03 13:30 ET
Cardiff Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-11-18 12:00 ET
Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative
2021-11-18 ET
Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative
2021-11-09 13:30 ET
Cardiff Oncology to Present at Upcoming Jefferies London Healthcare and Piper Sandler 33rd Annual Investor Conferences
2021-11-04 20:15 ET
Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates
2021-09-08 20:00 ET
Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival
2021-09-07 12:30 ET
Cardiff Oncology to Present at Upcoming Investor Conferences in September
2021-08-25 12:15 ET
Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer on September 8, 2021
2021-08-05 20:15 ET
Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates
2021-07-12 12:00 ET
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
2021-07-06 12:30 ET
Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021
2021-06-28 12:30 ET
Cardiff Oncology Added to the Russell 2000® and other FTSE Russell Indexes
2021-06-10 16:30 ET
Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors
2021-06-08 12:30 ET
Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer
2021-05-20 12:30 ET
Cardiff Oncology to Present at the Jefferies Virtual Healthcare Conference
2021-05-06 20:10 ET
Cardiff Oncology Announces First Quarter 2021 Results and Recent Highlights
2021-04-12 10:00 ET
Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues to Demonstrate Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC
2021-04-10 12:30 ET
Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC
2021-04-10 12:30 ET
Cardiff Oncology in Collaboration with MIT Presents Gene Signature Analyses Data Identifying Androgen-Independent Mechanism for Onvansertib-Abiraterone Synergy in mCRPC
2021-04-08 12:30 ET
Cardiff Oncology to Host Key Opinion Leader Webinar on Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer
2021-03-11 13:30 ET
Cardiff Oncology to Present at the Oppenheimer 31st Annual Healthcare Conference
2021-03-10 21:30 ET
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021
2021-03-03 13:30 ET
Cardiff Oncology to Present at H.C. Wainwright Global Life Sciences Conference
2021-02-25 21:10 ET
Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights
2021-02-24 13:30 ET
Cardiff Oncology to Participate in Gastrointestinal (GI) Oncology and Pancreatic Cancer Panel Discussion at the Cowen 41st Annual Health Care Conference
2021-02-16 16:54 ET
Cardiff Oncology to Present at the LifeSci Partners Precision Oncology Day
2021-02-11 13:00 ET
Cardiff Oncology Presents Phase 2 mCRPC Trial Data Showing a Two-Fold Increase in Efficacy with an Optimized Onvansertib Dosing Schedule
2021-01-26 13:00 ET
Cardiff Oncology Receives "Study May Proceed" from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
2021-01-15 13:00 ET
Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program
2020-12-21 21:15 ET
Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board
2020-12-06 13:30 ET
Cardiff Oncology Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed/Refractory AML
2020-11-23 13:30 ET
Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference
2020-11-05 21:05 ET
Cardiff Oncology Announces Third Quarter 2020 Results and Highlights
2020-10-20 12:30 ET
Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance
2020-09-30 04:14 ET
Cardiff Oncology Prices Public Offering
2020-09-29 20:02 ET
Cardiff Oncology Announces Proposed Public Offering
2020-09-17 12:00 ET
Cardiff Oncology Presents Data at ESMO Confirming Efficacy of Onvansertib and Durability of Response in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
2020-09-15 12:30 ET
Cardiff Oncology to Host Key Opinion Leader Call Discussing KRAS-Mutated Colorectal Cancer and Highlighting Data from Onvansertib Phase 1b/2 Trial
2020-09-14 12:30 ET
Cardiff Oncology to Present Data Further Demonstrating the Safety and Efficacy of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer Patients
2020-08-11 20:15 ET
Cardiff Oncology Announces Second Quarter 2020 Results and Highlights
2020-08-04 12:30 ET
Cardiff Oncology to Participate in Fireside Chat at the Virtual BTIG Biotechnology Conference
2020-07-30 12:30 ET
Cardiff Oncology to Participate in the William Blair Biotech Focus Conference
2020-06-16 12:30 ET
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
2020-06-15 12:30 ET
Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML
2020-06-09 12:15 ET
Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation
2020-05-29 12:30 ET
Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO
2020-05-28 12:15 ET
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
2020-05-27 12:15 ET
Cardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures
2020-05-19 12:15 ET
Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer
2020-05-13 12:15 ET
Cardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
2020-05-07 20:15 ET
Trovagene Announces First Quarter 2020 Results and Highlights
2020-05-06 12:15 ET
Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer
2020-04-28 12:15 ET
Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response
2020-04-22 12:30 ET
Trovagene Expands Board with Addition of Three Industry Leaders - James Armitage, MD, Lâle White, and Gary Pace, PhD
2020-04-08 12:30 ET
Trovagene to Present at the 19th Annual Needham Healthcare Conference
2020-04-01 12:15 ET
Trovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting
2020-03-05 13:15 ET
Trovagene Announces Three New Nominees for Election to Board of Directors
2020-02-27 21:15 ET
Trovagene Announces Fourth Quarter and Full-Year 2019 Results
2020-02-13 13:00 ET
Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients
2020-02-05 13:00 ET
Trovagene to Present New Clinical Data for Onvansertib in Metastatic Castration-Resistant Prostate Cancer at ASCO Genitourinary Cancers Symposium
2020-01-29 13:00 ET
Trovagene Receives Approximately $1.45 Million From Exercise of Warrants
2020-01-27 13:00 ET
Onvasertib Demonstrates Effectiveness as Pan-KRAS Inhibitor with Confirmed Tumor Regression and Clinical Benefit Achieved in KRAS-Mutated mCRC Patients
2020-01-21 13:00 ET
Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposium
2019-12-09 13:00 ET
Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASH
2019-12-04 13:00 ET
Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia (AML)
2019-11-14 13:00 ET
Trovagene Presents Positive Data in Metastatic Prostate Cancer Phase 2 Trial Showing Clinical Response in Patients Resistant to Zytiga®
2019-11-07 21:20 ET
Trovagene Announces Third Quarter 2019 Results and Highlights
2019-11-06 14:00 ET
Trovagene Announces Data from Acute Myeloid Leukemia (AML) Phase 1b/2 Trial of Onvansertib Chosen for Oral Presentation at ASH 2019 Annual Meeting
2019-10-25 17:37 ET
Trovagene Announces $5.0 Million Private Placement Priced At-the-Market
2019-10-22 12:15 ET
Trovagene Announces Positive Response to Treatment in Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer
2019-10-02 12:15 ET
Data Presented at ESMO Provides Rationale for Clinical Trial of Onvansertib in Subset of Patients with Highly-Aggressive Triple Negative Breast Cancer (TNBC)
2019-10-01 12:15 ET
Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) at ESMO
2019-09-30 12:15 ET
Positive Data from Trovagene Phase 1b/2 Study of Onvansertib Featured in Oral Presentation at European Society for Medical Oncology (ESMO) Conference
2019-09-19 12:15 ET
Trovagene Announces Successful Completion of Phase 1b Trial of Onvansertib in Acute Myeloid Leukemia (AML) and Initiation of Patient Enrollment in Phase 2
2019-09-03 12:15 ET
Trovagene to Present at the H.C. Wainwright 21st Annual Global Investment Conference
2019-08-26 12:00 ET
Trovagene Presents Positive Clinical Data from Ongoing Phase 2 Study of Onvansertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2019-08-15 12:15 ET
Trovagene to Present New Data from Onvansertib Phase 2 Study in Metastatic Castration-Resistant Prostate Cancer at Asia-Pacific Prostate Cancer Conference
2019-08-08 20:15 ET
Trovagene Announces Second Quarter 2019 Results and Highlights
2019-07-22 12:30 ET
ESMO Accepts Trovagene AML Clinical Trial Abstract for Oral Presentation
2019-07-15 12:30 ET
Trovagene Commences Non-Deal Investor Roadshow
2019-07-09 12:00 ET
Trovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers
2019-05-30 21:50 ET
Trovagene to Host Business Update Conference Call on June 7, 2019
2019-05-23 12:00 ET
Trovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD(TM) in Models of Colorectal Cancer
2019-04-05 12:15 ET
Trovagene Announces Update to Phase 1b/2 AML Trial Data Presented at AACR - Additional Patients Achieve Complete Response at Two Highest Dose Levels of Onvansertib
2019-04-05 12:00 ET
Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital
2019-04-02 12:00 ET
Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy
2019-04-01 17:00 ET
Phase 1b/2 Dose Escalation Trial of Onvansertib in Relapsed/Refractory AML Demonstrates Safety, Tolerability and Relative Durability with Complete Responses at Highest Dose Levels

SEC forms

Show financial reports only

SEC form 8
2026-02-25 13:30 ET
Cardiff Oncology published news for 2025 q4
SEC form 8
2026-02-25 13:30 ET
Cardiff Oncology published news for 2025 q4
SEC form 8
2026-02-24 17:09 ET
Cardiff Oncology published news for 2025 q4
SEC form 8
2026-02-24 17:09 ET
Cardiff Oncology reported for 2025 q4
SEC form 10
2026-02-24 17:07 ET
Cardiff Oncology reported for 2025 q4
SEC form 8
2025-11-06 16:08 ET
Cardiff Oncology published news for 2025 q3
SEC form 8
2025-11-06 16:08 ET
Cardiff Oncology reported for 2025 q3
SEC form 10
2025-11-06 16:00 ET
Cardiff Oncology reported for 2025 q3
SEC form 8
2025-07-29 20:10 ET
Cardiff Oncology published news for 2025 q2
SEC form 8
2025-07-29 20:10 ET
Cardiff Oncology reported for 2025 q2
SEC form 8
2025-07-29 20:10 ET
Cardiff Oncology published news for 2025 q2
SEC form 8
2025-07-29 20:10 ET
Cardiff Oncology published news for 2025 q2
SEC form 10
2025-07-29 20:00 ET
Cardiff Oncology reported for 2025 q2
SEC form 8
2025-05-08 20:10 ET
Cardiff Oncology published news for 2025 q1
SEC form 8
2025-05-08 20:10 ET
Cardiff Oncology reported for 2025 q1
SEC form 10
2025-05-08 20:00 ET
Cardiff Oncology reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Cardiff Oncology reported for 2025 q1
SEC form 8
2025-02-27 16:15 ET
Cardiff Oncology published news for 2024 q4
SEC form 8
2025-02-27 16:15 ET
Cardiff Oncology reported for 2024 q4
SEC form 10
2025-02-27 16:00 ET
Cardiff Oncology reported for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Cardiff Oncology reported for 2024 q4
SEC form 8
2024-11-07 16:07 ET
Cardiff Oncology published news for 2024 q3
SEC form 8
2024-11-07 16:07 ET
Cardiff Oncology reported for 2024 q3
SEC form 10
2024-11-07 16:00 ET
Cardiff Oncology reported for 2024 q3
SEC form 8
2024-08-08 16:06 ET
Cardiff Oncology published news for 2024 q2
SEC form 8
2024-08-08 16:06 ET
Cardiff Oncology reported for 2024 q2
SEC form 10
2024-08-08 16:00 ET
Cardiff Oncology reported for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Cardiff Oncology reported for 2024 q2
SEC form 8
2024-05-02 16:10 ET
Cardiff Oncology published news for 2024 q1
SEC form 8
2024-05-02 16:10 ET
Cardiff Oncology reported for 2024 q1
SEC form 10
2024-05-02 16:00 ET
Cardiff Oncology published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Cardiff Oncology published news for 2024 q1
SEC form 8
2024-02-29 16:08 ET
Cardiff Oncology published news for 2023 q4
SEC form 8
2024-02-29 16:08 ET
Cardiff Oncology reported for 2023 q4
SEC form 8
2024-02-29 16:08 ET
Cardiff Oncology published news for 2023 q4
SEC form 8
2024-02-29 16:08 ET
Cardiff Oncology published news for 2023 q4
SEC form 8
2024-02-29 16:08 ET
Cardiff Oncology published news for 2023 q4
SEC form 10
2024-02-29 16:00 ET
Cardiff Oncology reported for 2023 q4
SEC form 10
2024-02-29 00:00 ET
Cardiff Oncology reported for 2023 q4
SEC form 8
2023-11-02 16:06 ET
Cardiff Oncology reported for 2023 q3
SEC form 10
2023-11-02 16:02 ET
Cardiff Oncology reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Cardiff Oncology reported for 2023 q3
SEC form 6
2023-08-09 16:06 ET
Cardiff Oncology reported for 2023 q2
SEC form 10
2023-08-09 16:01 ET
Cardiff Oncology reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Cardiff Oncology reported for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Cardiff Oncology reported for 2023 q2
SEC form 6
2023-08-07 16:42 ET
Cardiff Oncology published news for 2023 q2
SEC form 6
2023-07-24 17:13 ET
Cardiff Oncology published news for 2023 q2
SEC form 6
2023-06-20 17:24 ET
Cardiff Oncology published news for 2023 q1
SEC form 6
2023-06-15 16:45 ET
Cardiff Oncology published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Cardiff Oncology reported for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Cardiff Oncology reported for 2023 q1
SEC form 6
2023-03-10 16:51 ET
Cardiff Oncology published news for 2022 q4
SEC form 6
2023-03-02 16:14 ET
Cardiff Oncology reported for 2022 q4
SEC form 10
2023-03-02 16:01 ET
Cardiff Oncology reported for 2022 q4
SEC form 10
2023-03-02 00:00 ET
Cardiff Oncology reported for 2022 q4
SEC form 8
2023-03-02 00:00 ET
Cardiff Oncology reported for 2022 q4
SEC form 6
2023-02-02 16:02 ET
Cardiff Oncology published news for 2022 q4
SEC form 6
2022-11-03 16:14 ET
Cardiff Oncology reported for 2022 q3
SEC form 10
2022-11-03 16:00 ET
Cardiff Oncology reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Cardiff Oncology reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Cardiff Oncology reported for 2022 q3
SEC form 6
2022-10-03 16:12 ET
Cardiff Oncology published news for 2022 q3
SEC form 6
2022-09-12 16:09 ET
Cardiff Oncology published news for 2022 q2
SEC form 6
2022-09-06 16:07 ET
Cardiff Oncology published news for 2022 q2
SEC form 6
2022-08-04 16:08 ET
Cardiff Oncology published news for 2022 q2
SEC form 10
2022-08-04 16:02 ET
Cardiff Oncology published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Cardiff Oncology reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Cardiff Oncology reported for 2022 q2
SEC form 6
2022-06-14 16:08 ET
Cardiff Oncology published news for 2022 q1
SEC form 6
2022-06-09 17:02 ET
Cardiff Oncology published news for 2022 q1
SEC form 6
2022-05-05 16:03 ET
Cardiff Oncology published news for 2022 q1
SEC form 10
2022-05-05 16:00 ET
Cardiff Oncology published news for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Cardiff Oncology reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Cardiff Oncology reported for 2022 q1
SEC form 6
2022-04-14 16:02 ET
Cardiff Oncology published news for 2022 q1
SEC form 6
2022-04-12 16:11 ET
Cardiff Oncology published news for 2022 q1
SEC form 6
2022-04-08 15:34 ET
Cardiff Oncology published news for 2022 q1
SEC form 6
2022-02-24 16:09 ET
Cardiff Oncology published news for 2021 q4
SEC form 10
2022-02-24 16:00 ET
Cardiff Oncology published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Cardiff Oncology published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Cardiff Oncology published news for 2021 q4
SEC form 6
2022-01-31 17:29 ET
Cardiff Oncology published news for 2021 q4
SEC form 6
2022-01-18 17:00 ET
Cardiff Oncology published news for 2021 q4
SEC form 6
2022-01-11 10:09 ET
Cardiff Oncology published news for 2021 q4
SEC form 6
2021-12-10 11:14 ET
Cardiff Oncology published news for 2021 q3
SEC form 6
2021-12-03 11:05 ET
Cardiff Oncology published news for 2021 q3
SEC form 6
2021-11-18 08:56 ET
Cardiff Oncology published news for 2021 q3
SEC form 6
2021-11-10 12:54 ET
Cardiff Oncology published news for 2021 q3
SEC form 6
2021-11-04 16:01 ET
Cardiff Oncology published news for 2021 q3
SEC form 10
2021-11-04 16:00 ET
Cardiff Oncology published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Cardiff Oncology published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Cardiff Oncology published news for 2021 q3
SEC form 6
2021-09-08 16:00 ET
Cardiff Oncology published news for 2021 q2
SEC form 6
2021-09-07 11:15 ET
Cardiff Oncology published news for 2021 q2
SEC form 6
2021-08-25 13:23 ET
Cardiff Oncology published news for 2021 q2
SEC form 10
2021-08-05 16:03 ET
Cardiff Oncology published news for 2021 q2
SEC form 6
2021-08-05 16:01 ET
Cardiff Oncology published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Cardiff Oncology published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Cardiff Oncology published news for 2021 q2
SEC form 6
2021-07-12 11:13 ET
Cardiff Oncology published news for 2021 q2
SEC form 6
2021-07-06 12:35 ET
Cardiff Oncology published news for 2021 q2
SEC form 6
2021-06-28 13:33 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-06-10 16:07 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-06-08 08:41 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-06-01 10:52 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-05-20 10:36 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-05-06 16:01 ET
Cardiff Oncology published news for 2021 q1
SEC form 10
2021-05-06 15:59 ET
Cardiff Oncology published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-04-28 16:01 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-04-12 08:33 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-04-08 15:03 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-03-11 13:43 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2021-03-03 12:57 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2021-02-25 16:02 ET
Cardiff Oncology published news for 2020 q4
SEC form 10
2021-02-25 16:01 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2021-02-24 11:21 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2021-02-16 13:43 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2021-02-11 10:39 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2021-01-26 11:19 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2021-01-15 11:34 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2020-12-21 16:18 ET
Cardiff Oncology published news for 2020 q3
SEC form 6
2020-12-07 13:22 ET
Cardiff Oncology published news for 2020 q3
SEC form 6
2020-11-23 11:54 ET
Cardiff Oncology published news for 2020 q3
SEC form 6
2020-11-05 16:09 ET
Cardiff Oncology published news for 2020 q3
SEC form 10
2020-11-05 16:00 ET
Cardiff Oncology published news for 2020 q3
SEC form 6
2020-10-20 11:59 ET
Cardiff Oncology published news for 2020 q3
SEC form 6
2020-09-30 16:09 ET
Cardiff Oncology published news for 2020 q2